ClearPoint Neuro, Inc. (CLPT) Q4 2025 Earnings Call Transcript

Greetings, and welcome to the ClearPoint Neuro, Inc. Fourth Quarter and Full Year 2025 Financial Results Conference Call. [Operator Instructions] As a reminder, this con ...

Aro Biotherapeutics Reports Positive Phase 1b Topline Results for ABX1100, a Muscle-targeted GYS1 siRNA, in Patients with Late-Onset Pompe Disease (LOPD)

Aro Biotherapeutics, a clinical-stage biotechnology company developing potent and tissue-targeted short-interfering RNA (siRNA) medicines in areas of high unmet need in rare muscle diseases, ...
The University of Alabama at Birmingham

Investigational gene therapy trial for rare kidney disease begins clinical trial at UAB

UAB is participating in a Phase I/II trial of AMT 191, a one time gene therapy designed to enable patients with classic Fabry disease to produce their own missing enzyme, potentially reducing the need ...

ClearPoint Neuro (CLPT) Earnings Call Transcript

Thank you. This is one of the largest unmet needs in all of medicine, and we at ClearPoint Neuro, Inc. believe we can play a crucial role in this exciting future. This foundation is made up of four ...